Kepler Capital Markets Downgrades Galapagos (NASDAQ:GLPG) to Reduce

Galapagos (NASDAQ:GLPG) was downgraded by stock analysts at Kepler Capital Markets from a “hold” rating to a “reduce” rating in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports.

A number of other equities research analysts also recently issued reports on the stock. Leerink Partners started coverage on shares of Galapagos in a research note on Monday, September 9th. They set a “market perform” rating and a $24.00 price target on the stock. Raymond James downgraded shares of Galapagos from an “outperform” rating to a “market perform” rating in a research note on Friday, August 2nd. Leerink Partnrs upgraded shares of Galapagos to a “hold” rating in a research report on Monday, September 9th. Finally, Royal Bank of Canada cut their price objective on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a research report on Friday, November 1st. Two research analysts have rated the stock with a sell rating and six have assigned a hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $30.75.

Galapagos Price Performance

GLPG stock opened at $25.17 on Wednesday. Galapagos has a one year low of $24.16 and a one year high of $42.46. The company’s fifty day moving average price is $28.76 and its 200-day moving average price is $27.54.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Headlands Technologies LLC grew its holdings in shares of Galapagos by 56.7% in the second quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 446 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Galapagos by 140.7% in the third quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 736 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Galapagos by 21.6% in the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 814 shares during the last quarter. Signaturefd LLC grew its holdings in shares of Galapagos by 48.1% in the second quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 1,258 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Galapagos by 63.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 1,510 shares during the last quarter. Institutional investors own 32.46% of the company’s stock.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.